Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pemphigus vulgaris: the other half of the story
Richard S. Kalish
Richard S. Kalish
View: Text | PDF
Commentary

Pemphigus vulgaris: the other half of the story

  • Text
  • PDF
Abstract

Authors

Richard S. Kalish

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Localization of split in PV and PF is explained by the desmoglein compen...
Localization of split in PV and PF is explained by the desmoglein compensation hypothesis. In skin (upper panels), Dsg3 is expressed at lower levels of the epidermis, whereas Dsg1 occurs at upper levels. In mucous membranes (lower panels), Dsg3 is present throughout the epidermis, and Dsg1 is present only at upper levels. In skin, anti-Dsg1 induces a split below the granular layer, where Dsg3 is lacking. In the oral mucosa, anti-Dsg3 alone is sufficient to induce suprabasal blisters, since Dsg1 is lacking at lower levels of the epidermis. However, the suprabasal blisters of skin in PV patients are associated with antibodies to both Dsg3 and Dsg1. Figure adapted from Mahoney et al. (7).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts